<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37211521</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2013-2514</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Nefrologia</Title><ISOAbbreviation>Nefrologia (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis.</ArticleTitle><Pagination><StartPage>6</StartPage><EndPage>47</EndPage><MedlinePgn>6-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nefroe.2023.05.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2013-2514(23)00081-0</ELocationID><Abstract><AbstractText>A significant number of patients with systemic lupus erythematosus (between 20% and 60% according to different reported series) develop lupus nephritis in the course of its evolution, which directly influences their quality of life and vital prognosis. In recent years, the greater knowledge about the pathogenesis of systemic lupus and lupus nephritis has allowed relevant advances in the diagnostic approach and treatment of these patients, achieving the development of drugs specifically aimed at blocking key pathogenic pathways of the disease. Encouragingly, these immunomodulatory agents have shown in well-powered, randomized clinical trials good clinical efficacy in the medium-term, defined as proteinuria remission and preservation of kidney function, with an acceptable safety profile and good patient tolerability. All this has made it possible to reduce the use of corticosteroids and other potentially more toxic therapies, as well as to increase the use of combined therapies. The present consensus document carried out by the Glomerular Diseases Working Group of the Spanish Society of Nephrology (GLOSEN), collects in a practical and summarized, but rigorous way, the best currently available evidence about the diagnosis, treatment, and follow-up of lupus nephritis patients, including cases of special situations, with the main objective of providing updated information and well-founded clinical recommendations to treating physicians, to improve the diagnostic and therapeutic approach to our patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Sociedad Espa&#xf1;ola de Nefrolog&#xed;a. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rojas-Rivera</LastName><ForeName>Jorge E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Hospital Universitario Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Servicio de Nefrolog&#xed;a e Hipertensi&#xf3;n, Madrid, Spain; Department of Medicine, Universidad Aut&#xf3;noma de Madrid, Servicio de Nefrolog&#xed;a, Madrid, Spain. Electronic address: jerori2003@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Carro</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hospital Universitario Cl&#xed;nico San Carlos, Servicio de Nefrolog&#xed;a. Madrid, Spain. Electronic address: claragarciacarro@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;vila</LastName><ForeName>Ana I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Hospital Dr. Peset, Servicio de Nefrolog&#xed;a, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espino</LastName><ForeName>Mar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Servicio de Nefrolog&#xed;a, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espinosa</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Universitario Reina Sof&#xed;a, Servicio de Nefrolog&#xed;a, Cordoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Ju&#xe1;rez</LastName><ForeName>Gema</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Hospital Universitario La Paz, Servicio de Nefrolog&#xed;a, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fulladosa</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Servicio de Nefrolog&#xed;a, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goicoechea</LastName><ForeName>Marian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Universitario Gregorio Mara&#xf1;&#xf3;n, Servicio de Nefrolog&#xed;a, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mac&#xed;a</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Universitario Nuestra Se&#xf1;ora de la Candelaria, Servicio de Nefrolog&#xed;a, Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Servicio de Nefrolog&#xed;a, Madrid, Spain; Instituto de Investigaci&#xf3;n Hospital Universitario 12 de Octubre, Servicio de Nefrolog&#xed;a, Madrid, Spain; Departamento de Medicina, Universidad Complutense, Servicio de Nefrolog&#xed;a, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porras</LastName><ForeName>Luis F Quintana</ForeName><Initials>LFQ</Initials><AffiliationInfo><Affiliation>Hospital Cl&#xed;nic de Barcelona, Servicio de Nefrolog&#xed;a, Barcelona, Spain; Departamento de Medicina, Universidad de Barcelona, IDIBAPS, Servicio de Nefrolog&#xed;a, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Praga</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Hospital Universitario 12 de Octubre, Servicio de Nefrolog&#xed;a, Madrid, Spain; Departamento de Medicina, Universidad Complutense, Servicio de Nefrolog&#xed;a, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Nefrologia (Engl Ed)</MedlineTA><NlmUniqueID>101778581</NlmUniqueID><ISSNLinking>2013-2514</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biological therapy</Keyword><Keyword MajorTopicYN="N">Immunosupressive treatment</Keyword><Keyword MajorTopicYN="N">Kidney biopsy</Keyword><Keyword MajorTopicYN="N">Lupus nephritis</Keyword><Keyword MajorTopicYN="N">Nephrotic syndrome</Keyword><Keyword MajorTopicYN="N">Renal outcomes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>21</Day><Hour>22</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37211521</ArticleId><ArticleId IdType="doi">10.1016/j.nefroe.2023.05.006</ArticleId><ArticleId IdType="pii">S2013-2514(23)00081-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>